New cocktail of targeted drugs and chemo takes on pancreatic cancer

NCT ID NCT05669482

Ongoing Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest dose and see if it shrinks tumors or slows the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avutometinib and defactinib (targeted drugs) plus gemcitabine and nab-paclitaxel (chemotherapy)
What this could lead to: If successful, this could lead to a more effective first-line treatment for metastatic pancreatic cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply to all patients. The drug combination may cause significant side effects or fail to improve outcomes over standard chemo alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm metastatic malignant neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS ACTIVATING MUTATION MALIGNANT NEOPLASM OF PANCREAS METASTATIC CANCER NEOPLASMS, PANCREATIC PANCREAS CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
New York Presbyterian/Weill-Cornell Medical Center

New York, New York, 10021, United States
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94158, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.